What changed: r1 to r2
No authored reason recorded.
Retrieval clocks and internal hashes are excluded. Changed source or accounting definitions are not automatically an economic restatement. The authored reason describes the destination revision.
| Field | Before | After |
|---|---|---|
| /business/description | Not yet authored. | We are a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea ("OSA"). Our proprietary Inspire system is the first FDA, European Union ("EU") Regulation No. 2017/745 ("MDR" or "EU Medical Devices Regulation"), and Japan Pharmaceuticals and Medical Devices Agency-approved neurostimulation technology of its kind that provides a safe and effective treatment for patients with moderate to severe OSA. We have developed a novel, closed-loop solution that continuously monitors a patient’s breathing and delivers mild hypoglossal nerve stimulation to maintain an open airway. A significant body of clinical data, which includes a publication in the New England Journal of Medicine , multiple publications in leading respiratory, ear, nose and throat ("ENT") and sleep medicine journals, and more than 385 peer-reviewed publications, supports the safety and efficacy of Inspire therapy. Inspire therapy received premarket approval ("PMA") from the FDA in. |
| /business/drivers/0 | Not yet authored. | customers are generally reimbursed for the cost of patient treatment by various third-party payors, such as commercial insurance providers and Medicare. |
| /business/drivers/1 | Not yet authored. | patent applications, and 73 pending foreign patent applications that cover aspects of our Inspire system and future product concepts. |
| /business/drivers/2 | Not yet authored. | We believe that by enhancing interconnectivity, simplifying the care pathway, and closely tracking outcomes, we can optimize the customer experience and. |
| /earnings/next_report_date | None | 2026-11-01 |
| /earnings/source | No published note dates the next report. | estimated from 10-Q filed 2026-08-03 plus 90 days |
| /memory/bands/10d/p10 | -11.128 | -19.869 |
| /memory/bands/10d/p50 | 0.583 | -0.298 |
| /memory/bands/10d/p90 | 12.694 | 19.012 |
| /memory/bands/10d/p_up | 0.527 | 0.487 |
| /memory/bands/1d/p10 | -3.412 | -5.141 |
| /memory/bands/1d/p50 | 0.096 | 0.115 |
| /memory/bands/1d/p90 | 3.84 | 7.303 |
| /memory/bands/1d/p_up | 0.51 | 0.52 |
| /memory/bands/5d/p10 | -7.412 | -14.125 |
| /memory/bands/5d/p50 | 0.77 | 0.476 |
| /memory/bands/5d/p90 | 9.213 | 11.905 |
| /memory/bands/5d/p_up | 0.553 | 0.513 |
| /meta/as_of | 2026-09-17 | 2026-09-18 |
| /meta/business_authored | None | False |
| /meta/extract_accession | None | 0001609550-26-000016 |
| /meta/extract_filed | None | 2026-02-13 |
| /meta/extract_form | None | 10-K |
| /meta/extract_source | None | filing |
| /meta/extract_url | None | https://www.sec.gov/Archives/edgar/data/1609550/000160955026000016/insp-20251231.htm |
| /meta/revision | 1 | 2 |
| /thesis/view | Not yet authored. | |
| /thesis/what_changes_it | Not yet authored. |